CLSDのチャート
CLSDの企業情報
| symbol | CLSD |
|---|---|
| 会社名 | Clearside Biomedical Inc （クリアサイド・バイオメディカル） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 クリアサイド・バイオメディカル(Clearside Biomedical Inc.)は目のまばゆい病気を治療するための業界初の薬物療法を開発している臨床生物医薬品会社である。同社の製品候補は、網膜に影響を及ぼす病気に重点を置く。網膜は、目の内部を覆う組織であり、主に視力の原因である。網膜に隣接する層である脈絡膜は、網膜に血液、酸素、栄養を供給する。そのマイクロインジェクターでは、脈絡膜と強膜と呼ばれる眼の外側保護層との間に位置する脈絡膜上腔（SCS）内に薬物が注入されて広がる。脈絡膜上皮の注射では、眼の中心部を占めるゼリー様物質である硝子体への薬物の注射など、他の眼内薬物投与技術と比較して、その脈絡膜の生成物候補が網膜および脈絡膜に直接的に投与される。 クリアサイド・バイオメディカルは米国のバイオ医薬品企業。後期臨床段階で、主に眼科疾患のための薬物送達技術の開発に焦点を当てる。同社の登録商標製品である「SCSマイクロインジェクタ―」は網膜と、黄斑浮腫を伴う病気に関連する脈絡膜を治療するために使用される。本社はジョ―ジア州アルファレッタ。 Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. Clearside's proprietary SCS Microinjector® targets the suprachoroidal space (SCS®) and offers unique access to the macula, retina and choroid where sight-threatening disease often occurs. The Company's SCS injection platform is an inherently flexible, in-office, non-surgical procedure, intended to provide targeted delivery to the site of disease and to work with both established and new formulations of medications. |
| 本社所在地 | 900 North Point Parkway Suite 200 Alpharetta GA 30005 USA |
| 代表者氏名 | Christy L. Shaffer Christy L. Shaffer |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 678-270-3631 |
| 設立年月日 | 40664 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2016年 |
| 従業員数 | － |
| url | www.clearsidebio.com |
| nasdaq_url | https://www.nasdaq.com/symbol/clsd |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -71.68200 |
| 終値（lastsale） | 5.8001 |
| 時価総額（marketcap） | 185743695.8223 |
| 時価総額 | 時価総額（百万ドル） 185.10000 |
| 売上高 | 売上高（百万ドル） 0.21000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 110.51800 |
| 当期純利益 | 当期純利益（百万ドル） -72.13700 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Clearside Biomedical Inc revenues decreased from $135K to $0K. Net loss increased 55% to $37.3M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development - Balancing val increase of 62% to $29.8M (expense) General and administrative increase of 27% to $5.2M (expense). |
CLSDのテクニカル分析
CLSDのニュース
Clearside Biomedical, Inc.''s (CLSD) CEO George Lasezkay on Q1 2022 Results - Earnings Call Transcript 2022/05/12 01:11:06 Seeking Alpha
Clearside Biomedical, Inc. (NASDAQ:NASDAQ:CLSD) Q1 2022 Earnings Conference Call May 11, 2022, 04:30 PM ET Company Participants Jenny Kobin - Investor Relations George Lasezkay - President…
Clearside Biomedical GAAP EPS of -$0.13 misses by $0.10, revenue of $0.35M misses by $5.85M 2022/05/11 20:12:03 Seeking Alpha
Clearside Biomedical press release (NASDAQ:CLSD): Q1 GAAP EPS of -$0.13 misses by $0.10.Revenue of $0.35M (+1066.7% Y/Y) misses by $5.85M.
Clearside Biomedical Announces First Quarter 2022 Financial Results and Provides Corporate Update 2022/05/11 20:05:00 GlobeNewswire
- First Approved Suprachoroidal Product, XIPERE ® , Now Commercially Available in U.S. -
Clearside Biomedical Q1 2022 Earnings Preview (NASDAQ:CLSD) 2022/05/10 21:35:05 Seeking Alpha
Clearside Biomedical (CLSD) is scheduled to announce Q1 earnings results on Wednesday, May 11th, after market close.The consensus EPS Estimate is -$0.01 and the consensus Revenue…
Clearside Biomedical to Report First Quarter 2022 Financial Results and Provide Corporate Update on Wednesday, May 11, 2022 2022/04/29 11:05:00 GlobeNewswire
ALPHARETTA, Ga., April 29, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that its first quarter 2022 financial results will be reported on Wednesday, May 11, 2022 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.
Clearside Biomedical Inc. (NASDAQ:CLSD) Stock Ripped -21.09% Year-To-Date, What Will Happen Next? 2022/04/09 18:00:00 Marketing Sentinel
In last trading session, Clearside Biomedical Inc. (NASDAQ:CLSD) saw 0.36 million shares changing hands with its beta currently measuring 2.09. Company’s recent per share price level of $2.17 trading at -$0.2 or -8.44% at ring of the bell on the day assigns it a market valuation of $127.70M. That closing price of CLSD’s stock is … Clearside Biomedical Inc. (NASDAQ:CLSD) Stock Ripped -21.09% Year-To-Date, What Will Happen Next? Read More »
Clearside Biomedical to Present at the Needham Virtual Healthcare Conference 2022/04/06 11:05:00 GlobeNewswire
ALPHARETTA, Ga., April 06, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer, will present at the Needham Virtual Healthcare Conference on Wednesday, April 13, 2022 at 3:45 p.m. ET.
Thinking about buying stock in ORIC Pharmaceuticals, WiMi Hologram Cloud, Clearside Biomedical, Stronghold Digital Mining, or GasLog Partners? 2022/03/28 13:31:00 Benzinga
NEW YORK , March 28, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ORIC, WIMI, CLSD, SDIG, and GLOP. … Full story available on Benzinga.com
Bausch Health, Clearside launch vision disorder therapy Xipere in US 2022/03/28 12:15:52 Seeking Alpha
Bausch Health (BHC) and Clearside Biomedical (CLSD) launched eye disorder therapy Xipere (triamcinolone acetonide injectable suspension) in the U.S.The companies said Xipere is the…
Clearside Biomedical Inc. (NASDAQ: CLSD) Is One Of The Hottest Stocks Right Now. 2022/03/22 15:30:00 Stocks Register
Clearside Biomedical Inc. (NASDAQ:CLSD) price closed lower on Monday, March 21, dropping -10.31% below its previous close. >> 5 Best Growth Stocks for 2022 << >> 5 Best Growth Stocks for 2022 << A look at the daily price movement shows that the last close reads $2.62, with intraday deals fluctuated between $2.33 and $2.7124. … Clearside Biomedical Inc. (NASDAQ: CLSD) Is One Of The Hottest Stocks Right Now. Read More »
FY2021 Earnings Forecast for Clearside Biomedical, Inc. Issued By Wedbush (NASDAQ:CLSD) 2021/12/24 11:26:42 Dakota Financial News
Clearside Biomedical, Inc. (NASDAQ:CLSD) – Stock analysts at Wedbush reduced their FY2021 EPS estimates for Clearside Biomedical in a research note issued to investors on Tuesday, December 21st. Wedbush analyst A. Argyrides now anticipates that the company will post earnings of ($0.43) per share for the year, down from their prior estimate of ($0.42). Wedbush […]
HC Wainwright Reaffirms Buy Rating for Clearside Biomedical (NASDAQ:CLSD) 2021/12/23 08:46:41 Dakota Financial News
HC Wainwright reissued their buy rating on shares of Clearside Biomedical (NASDAQ:CLSD) in a research report report published on Wednesday, Price Targets.com reports. The firm currently has a $10.00 price target on the stock. CLSD has been the subject of several other reports. JMP Securities restated a buy rating and set a $11.00 target price []
Diabetic Macular Edema Market Size, Landscape, Industry Analysis, Business Outlook, Current and Future Growth By 2028 | Pfizer Inc, Allergan PLC, Novartis AG, Clearside Biomedical Inc, Ariam Pharmaceuticals, Valeant Pharmaceuticals, Regenron PLC, Bayer AG 2021/12/14 11:13:00 OpenPR
New Jersey, United States,- Verified Market Research has recently published a research report titled, Diabetic Macular Edema Market Size, and Forecast 2021-2028, Breakdown Data by Manufacturers, Key Regions, Types and Application. Primary and secondary research methodologies have been used to
Clearside Biomedical Added to the Nasdaq Biotechnology Index 2021/12/13 21:05:00 Intrado Digital Media
ALPHARETTA, Ga., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that the Company will be added to the Nasdaq Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 20, 2021.